Changes in Cognitive Function in Patients with Subclinical Atrial Fibrillation Treated with Apixaban or Aspirin: A Sub-Study from the ARTESiA Trial

2 September 2024 (16:03 - 16:15)

Organised by:

Video

Sign in for access options

About the speaker

Doctor Lena Rivard

Montreal Heart Institute, Montreal (Canada)

4 More presentations in this session

Presentation thumbnail

Long-acting Factor XI Inhibition and Periprocedural Bleeding: A Secondary Analysis from AZALEA-TIMI 71

Doctor S. Patel (Boston, US)

Presentation thumbnail

Aspirin and hemocompatibility related adverse events after LVAD implantation in patients with diabetes mellitus, obesity and atrial fibrillation: the ARIES-HM3 randomized clinical trial

Doctor N. Uriel (New York, US)

Presentation thumbnail

Efficacy and safety of anticoagulation in patients with device-detected atrial fibrillation by indication for acetylsalicylic acid therapy

Professor R. Schnabel (Hamburg, DE)

Presentation thumbnail

The Association between Age and Clinical Outcomes in Patients with Subclinical Atrial Fibrillation Treated with Apixaban: Insights from the ARTESiA Trial

Associate Professor M. Proietti (Milan, IT)

Access the full session

Session thumbnail

Smaller trials, trial updates, and other studies on antiplatelet and antithrombotic therapies

The Event

Event poster

ESC Congress 2024

2 September 2024 16:03 CET

You may be interested in

Congress Session

Smaller trials, trial updates, and other studies on antiplatelet and antithrombotic therapies

Congress Presentation

Ablate or anticoagulate to prevent further cognitive dysfunction in atrial fibrillation?

Congress Session

Smaller trials, trial updates, and other studies: atrial fibrillation detection, prevention and treatment

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources